Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients

Paolisso, Giuseppe; Barbagallo, M; Petrella, Giuseppina; Ragno, Emilia; Barbieri, Michelangela; Giordano, Mauro; Varricchio, M

doi:10.1016/s0021-9150(99)00352-4

Cited by 157 publications

(110 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effects of statins on insulin sensitivity had been reported in the past years, simvastatin and atorvastatin may improve insulin sensitivity in diabetic patients [21] ; however, others have reported that simvastatin either did not change or worsened insulin sensitivity in diabetic patients [22,23] . And there are no reports exist of their mechanism of action in insulin resistance, obesity animal models.…”

Section: Discussionmentioning

confidence: 97%

Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate

et al. 2009

View full text Add to dashboard Cite

Aim: To examine the mechanisms underlying the effects of atorvastatin on glucose and lipid metabolism. Methods: Mice with insulin resistance and obesity induced by monosodium glutamate (MSG) were used. Atorvastatin (80 mg·kg -1 ·d -1 ) or vehicle control treatment was given orally once a day for 30 days. Plasma levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and free fatty acids were monitored. Serum insulin and glucose concentrations were used to calculate the insulin resistance index and insulin sensitivity index using a homeostasis model. Body length, waistline circumference, intraperitoneal adipose tissue mass, and total body mass were measured. Semi-quantitative RT-PCR and Western analysis were used to determine the expression of inflammatory factors and proteins involved in inflammation signaling pathways. Results: Atorvastatin improved insulin sensitivity, ameliorated glucose tolerance, and decreased plasma levels of total cholesterol, triglycerides, LDL-C, HDL-C and free fatty acids. Semi-quantitative RT-PCR and Western analysis revealed increased expression of interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) in serum and adipose tissue in MSG obese mice. Atorvastatin treatment decreased expression of IL-6, TNF-α, nuclear factor κB (NF-κB) and I-kappa-B (IκB) kinase-β, but increased the expression of IκB, in adipose tissue. Conclusion: Atorvastatin is a potential candidate for the prevention and therapy of diseases associated with insulin resistance such as type 2 diabetes mellitus and cardiovascular disease. One possible mechanism underlying the effects of atorvastatin on glucose and lipid metabolism may be to ameliorate a state of chronic inflammation.

show abstract

Section: Discussionmentioning

confidence: 97%

Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate

et al. 2009

View full text Add to dashboard Cite

show abstract

“…With both groups having a total cholesterol concentration of o5 mmol/l at the start of the study, it is unlikely that dietary intervention would make a further significant impact on cholesterol concentration. Also, a number of recent reports suggest that both statin therapy (Paolisso et al, 2000) and aspirin improve insulin sensitivity (O'Keefe et al, 1999). If this is the case, it may be that the insulin sensitising effects of the LGI diet were masked by the higher statin and aspirin usage in the control group.…”

Section: Discussionmentioning

confidence: 99%

A prospective randomised trial to determine the efficacy of a low glycaemic index diet given in addition to healthy eating and weight loss advice in patients with coronary heart disease

et al. 2003

View full text Add to dashboard Cite

Objective: Recent epidemiological and prospective trial evidence suggests that consumption of a low glycaemic index (LGI) diet will reduce coronary risk. We hypothesise that introduction of an LGI diet will improve the metabolic profile of patients who have undergone coronary artery bypass grafting. Design: We conducted a randomised parallel group trial comparing a control group (n ¼ 29, age 61.879 y), who received currently advocated healthy eating dietary advice only, to an intervention group, who received healthy eating advice emphasising LGI carbohydrates (n ¼ 26, age 63.679.4 y) over a 12-week period in free-living patients with coronary heart disease. Outcome measures included fasting glucose, insulin, total cholesterol, high-density lipoprotein cholesterol, very lowdensity lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides. Results: A significant lower dietary glycaemic index was achieved in the group assigned to an LGI diet compared to the healthy eating control group (7171 vs 8171); fibre intake was also higher in the LGI group (2071 vs 1571 g). All biochemical markers of glucose and lipid metabolism measured were similar after 12 weeks of the LGI diet or control diet. Discussion: The LGI group achieved a significant LGI and a higher dietary fibre intake. However, there was no measurable significant effect of either the LGI diet or the health eating diet on lipid levels; this may have been hidden by concurrent drug therapy.

show abstract

“…Administration of ACE-I/ARB and statin was recorded, because these drugs have been reported to reduce insulin resistance. 16 …”

Section: Clinical Evaluationmentioning

confidence: 99%

Postprandial hyperglycemia and hyperinsulinemia associated with renal arterio-arteriolosclerosis in chronic kidney disease

et al. 2010

View full text Add to dashboard Cite

Hypertension has an important function in the formation of renal arterio-arteriolosclerosis. However, renal arterioarteriolosclerosis is sometimes found in biopsy specimens of normotensive patients, which indicates unknown factors may contribute to renal arterio-arteriolosclerosis. In this study, we aimed to evaluate the effects of glucose metabolism/insulin resistance on renal arterio-arteriolosclerosis. Forty-eight patients with biopsy-proven non-diabetic chronic glomerular disease were included. Renal arterio-arteriolosclerosis was evaluated as the percentage of vessels showing hyaline changes or wall thickening. We correlated renal arterio-arteriolosclerosis with clinical parameters including indices obtained by 75 g oral glucose tolerance test. Of the 48 patients, 30 had hypertension. The results of univariate analysis showed significant association of renal arterio-arteriolosclerosis with hypertension, increased serum creatinine (S-Cr), hypertriglyceridemia, increased 2-h plasma glucose (PG) and increased 2-h plasma insulin (PI). In stepwise multiple regression analysis, hypertension (b¼0.344, P¼0.009), S-Cr (b¼0.287, P¼0.03) and 2-h PG (b¼0.274, P¼0.03) were independently associated with renal arterioarteriolosclerosis. Eleven of the 30 hypertensive patients did not have renal arterio-arteriolosclerosis. The hypertensive patients with renal arterio-arteriolosclerosis showed significantly higher 2-h PG (134 ± 25 vs. 106 ± 26 mg per 100 ml, P¼0.008) and higher 2-h PI (67.7 ± 34.9 vs. 48.3 ± 30.0 lU ml À1 , P¼0.04) compared with those without renal arterio-arteriolosclerosis, but the difference in S-Cr was not significant. Postprandial hyperglycemia and hyperinsulinemia may contribute to the formation of renal arterio-arteriolosclerosis independently of hypertension.

show abstract

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients

Cited by 157 publications

References 35 publications

Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate

Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate

A prospective randomised trial to determine the efficacy of a low glycaemic index diet given in addition to healthy eating and weight loss advice in patients with coronary heart disease

Postprandial hyperglycemia and hyperinsulinemia associated with renal arterio-arteriolosclerosis in chronic kidney disease

Contact Info

Product

Resources

About